DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Peter Lawson - 2 Lawson - 2 Scott Schoenhaus - 1 Chris Gibson - 1 Jensen Huang - 1 Leerink - 1 Mani Foroohar - 1 Foroohar - 1
Top related locs:
U.S biopharma Biohive
Top related orgs:
Therapeutics - 2 Barclays - 2 Analysts - 1 Capital - 1 Nvidia - 1 ARK Investment Management - 1 REC - 1 CCM - 1

Search resuls for: "Peter Lawson"


3 mentions found


☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
  + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +10 min
Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.
Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive
☆ Barclays upgrades a little-known biotech stock that it says can more than double
  + stars: | 2024-05-10 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Barclays thinks Relay Therapeutics stock can benefit from progress in drug tests to get a proposed breast cancer treatment approved, boosting the stock. Relay stock has slumped 40% in 2024. "We believe the 2H update will help show the superior efficacy/safety profile for Relay's PI3Kalpha (RLY-2608) over existing PI3Kalpha inhibitors like alpelisib and inavolisib," Lawson said. Barclays sees a 70% chance of positive data emerging from an expanded Phase 1 study of RLY-2608 (+fulvestrant) in advanced HR+/HER2- breast cancer. That outcome, "all else equal, could potentially drive the stock up $5 while negative data could drive the stock down $2," the bank said.
Persons: Peter Lawson, Relay's, Lawson Organizations: Barclays, Therapeutics
☆ UK police identify body found in river as Nicola Bulley
  + stars: | 2023-02-20 | by ( ) www.reuters.com   time to read: +1 min
LONDON, Feb 20 (Reuters) - British police on Monday identified a body found in the River Wyre in northern England as Nicola Bulley, a mother of two who went missing last month sparking a large search that captured media and public attention. "Sadly we are now able to confirm that yesterday we recovered Nicola Bulley from the River Wyre," Lancashire Police Assistant Chief Constable Peter Lawson told a news conference. Bulley, 45, was last seen walking her dog near the river in Lancashire on Jan. 27. Lancashire Police said an underwater search team and specialist officers had recovered a body from the water on Sunday. The family statement went on to heavily criticise media intrusion during the search.
0 next >>
Total: 3